M. Lainchbury

发表

CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

S. Robinson, M. Walton, K. Boxall, 2012, Clinical Cancer Research.

Checkpoint kinase inhibitors: a patent review (2009 – 2010)

I. Collins, M. Lainchbury, 2011, Expert opinion on therapeutic patents.

A protecting group free synthesis of (+/-)-neostenine via the [5 + 2] photocycloaddition of maleimides.

P. Hirst, M. Lainchbury, K. Booker‐Milburn, 2008, The Journal of organic chemistry.

Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).

S. Robinson, R. V. van Montfort, M. Lamers, 2016, Journal of medicinal chemistry.

Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR.

C. Eigenbrot, Ivana Yen, S. Sideris, 2016, ACS medicinal chemistry letters.

Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors

M. Walton, K. Boxall, G. Aherne, 2012, Journal of medicinal chemistry.

Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor.

Siew K. Yeap, C. Eigenbrot, Ivana Yen, 2016, Journal of medicinal chemistry.

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.

Belen Dominguez-Fernandez, C. Eigenbrot, Ivana Yen, 2015, Journal of medicinal chemistry.

Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation

Siew K. Yeap, C. Eigenbrot, Ivana Yen, 2014, Journal of medicinal chemistry.

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

M. Walton, N. Perkins, K. Boxall, 2015, Oncotarget.

Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).

Hoai An Le Thi, E. Gancia, BinQing Wei, 2021, ACS medicinal chemistry letters.

Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).

R. V. van Montfort, K. Boxall, G. Aherne, 2016, Journal of medicinal chemistry.

Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).

Hoai An Le Thi, E. Gancia, Weiru Wang, 2021, ACS medicinal chemistry letters.